Group 1 - Idex reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and up from $1.83 per share a year ago, representing an earnings surprise of 0.49% [1] - The company posted revenues of $862.9 million for the quarter ended December 2024, which was 0.24% below the Zacks Consensus Estimate, and an increase from $788.9 million year-over-year [2] - Idex has surpassed consensus EPS estimates in all four of the last quarters, but has only topped consensus revenue estimates once in the same period [2] Group 2 - The stock has gained approximately 4.6% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.99 on revenues of $846.77 million, and for the current fiscal year, it is $8.47 on revenues of $3.47 billion [7] Group 3 - The Zacks Industry Rank indicates that the Manufacturing - General Industrial sector is currently in the bottom 32% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Financial Performance - Fourth quarter net sales were $862.9 million, an increase of 9% overall and 3% organically compared to Q4 2023[3] - Full year net sales totaled $3.3 billion, flat overall and down 2% organically from 2023[3] - Reported diluted EPS for Q4 was $1.62, up 13%, while adjusted diluted EPS was $2.04, up 11%[3] - Net sales for Q4 2024 increased by 19% to $862.9 million, driven by the acquisition of Mott, while organic sales remained flat[18] - Total net sales for Q4 2024 reached $862.9 million, a 9.4% increase from $788.9 million in Q4 2023[32] - For the year ended December 31, 2024, total net sales were $3,268.8 million, slightly down from $3,273.9 million in 2023, reflecting a 0.2% decrease[32] - Reported net income for Q4 2024 was $123.2 million, up from $108.3 million in Q4 2023, while full-year net income decreased to $504.6 million from $595.6 million[39] Cash Flow and Earnings - Operating cash flow for Q4 was $173 million, down 14%, representing 140% of net income, a decrease from 185%[3] - Free cash flow for Q4 was $157 million, down 12%, yielding a conversion of 101% of adjusted net income, down from 129%[3] - Free cash flow for Q4 2024 was $157.1 million, down from $179.4 million in Q4 2023, with full-year free cash flow at $603.0 million compared to $626.8 million in 2023[39] - Adjusted EBITDA for Q4 2024 reached $227.5 million, compared to $203.6 million in Q4 2023, with a full-year adjusted EBITDA of $874.3 million, slightly down from $899.6 million[39] Segment Performance - The Health & Science Technologies segment reported net sales of $373.2 million, an increase of 19.4% compared to Q4 2023[10] - The Fire & Safety/Diversified Products segment achieved record sales of $192.9 million, up 13.9% compared to Q4 2023[10] - Organic sales growth for Fluid & Metering Technologies was 3%, while Health & Science Technologies experienced a decline of 7%[37] Guidance and Projections - Full year organic sales are projected to increase by 1% to 3% over the prior year[3] - First quarter 2025 organic sales are projected to decrease by 3% to 4% from the prior year period[3] - The company anticipates organic sales growth and earnings per share guidance for Q1 2025 and full year 2025[19] - Estimated diluted EPS for Q1 2025 is projected to be between $1.18 and $1.24, with full-year estimates ranging from $6.56 to $6.96[40] - The company anticipates a change in organic sales for 2025 to be between -4% and 3%, with net sales expected to increase by 1% to 6%[40] Balance Sheet and Assets - Total assets as of December 31, 2024, reached $6.745 billion, an increase from $5.865 billion in 2023[28] - Cash and cash equivalents at the end of 2024 were $620.8 million, up from $534.3 million at the end of 2023[28] - IDEX's goodwill increased to $3.252 billion in 2024 from $2.838 billion in 2023, reflecting recent acquisitions[28] - IDEX's total liabilities increased to $2.951 billion in 2024 from $2.324 billion in 2023, indicating higher leverage due to acquisitions[28] Profitability Metrics - The company reported a gross profit of $367.1 million for Q4 2024, compared to $336.8 million in Q4 2023[26] - Adjusted gross profit for Q4 2024 was $372.1 million, compared to $337.2 million in Q4 2023, indicating a growth of 10.3%[36] - The gross margin for Q4 2024 was 42.5%, slightly down from 42.7% in Q4 2023[36] - Estimated net income margin for Q1 2025 is expected to be between 11.2% and 11.8%, while the full-year margin is projected to be between 14.7% and 15.3%[41] Expenses and Charges - Restructuring expenses and asset impairments totaled $3.9 million for Q4 2024, compared to $2.7 million in Q4 2023[38] - The company reported a fair value inventory step-up charge of $5.0 million for Q4 2024, up from $0.4 million in Q4 2023[36] - Total depreciation and amortization expenses for the year ended December 31, 2024, were $68.5 million, compared to $57.2 million in 2023, reflecting an increase of 19.0%[32]

IDEX Corporation (IEX) is scheduled to release fourth-quarter 2024 results on Feb. 4, after market close.The Zacks Consensus Estimate for fourth-quarter earnings has remained steady in the past 60 days. The company has an impressive earnings surprise history, having outperformed the consensus estimate in each of the preceding four quarters, the average surprise being 2.9%.The consensus estimate for revenues is pegged at $865 million, indicating an increase of 9.6% from the prior-year quarter’s figure. The c ...

Reference is made to the private placement (the “Private Placement”) completed in IDEX Biometrics ASA (the “Company”) on 17 September 2024, and to the subsequent offering completed in the Company on 29 November 2024 (the “Subsequent Offering”). The subscribers in the Private Placement and the Subsequent Offering were allocated two warrants, Warrants A and Warrants B (collectively, the “Warrants”), respectively, issued by the Company for every two Offer Shares allocated to, and paid by, them in the Private P ...

Goodbridge Capital Corp. Announces Execution of Definitive Agreement and Updates Proposed Qualifying Transaction With IDEX Metals CorpDecember 03, 2024 1:00 PM EST | Source: Goodbridge Capital Corp.Vancouver, British Columbia--(Newsfile Corp. - December 3, 2024) - Goodbridge Capital Corp. (TSXV: GODB.P) ("Goodbridge" or the "Company"), a capital pool company listed on the TSX Venture Exchange (the "Exchange"), is pleased to announce that, further to its news release dated May 28, 2024, it has ...

­­­­­Reference is made to the subsequent offering in IDEX Biometrics ASA (the “Company”) approved by the Extraordinary General Meeting on 9 October 2024, including notifications with regards to primary insiders’ subscriptions on 28 November 2024 and 2 December 2024. The Company’s Chair, Morten Opstad, subscribed to 1,000,000 shares, at NOK 0.15 per share, through his associated companies. Opstad was allocated 250,000 shares for K-Konsult AS and 750,000 shares for Marc O Polo Norge AS. After the subscription ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from IDEX Biometrics ASA (the “Company”) on 13 November 2024 regarding the commencement of the subscription period (the “Subscript ...

Reference is made to the subsequent offering in IDEX Biometrics ASA (the “Company”) approved by the Extraordinary General Meeting on 9 October 2024. The Company’s Chair, Morten Opstad, has subscribed to 1,000,000 shares, at NOK 0.15 per share. Whereof he subscribed to 250,000 shares for K-Konsult AS, and 750,000 shares for Marc O Polo Norge AS. The final allocation, including the primary insider registration form, will be notified later today. For further information contact:Marianne Bøe, Head of Investo ...

Reference is made to the stock exchange notices from IDEX Biometrics ASA on 13 November 2024 and 26 November 2024 regarding the subscription period (the “Subscription Period”), in the subsequent offering (the “Subsequent Offering”). Shareholders who participated in this offering will also receive warrants to subscribe for additional shares at the same price (NOK 0.15 per share). The Subscription Period expired 29 November 2024 at 16:30 CET. The company has been informed by Arctic Securities AS, that at the ...

Reference is made to the stock exchange notices from IDEX Biometrics ASA on 13 November 2024 and 26 November 2024 regarding the subscription period (the “Subscription Period”), in the subsequent offering (the “Subsequent Offering”) consisting of up to 140 million new shares at a subscription price of NOK 0.15 per share. Shareholders participating in this offering will also receive warrants to subscribe for additional shares at the same price (NOK 0.15 per share). The Subscription Period will end today, 29 N ...